| 2024-05-14 |
详情>>
股本变动：
变动后总股本267.90万股
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-1.33美元,归母净利润-316.8万美元,同比去年增长62.75%
|
| 2024-05-14 |
财报披露：
美东时间 2024-05-14 盘后发布财报
|
| 2024-04-10 |
复牌提示：
2024-04-09 19:50:00 停牌，复牌日期 2024-04-10 09:00:00
|
| 2024-04-10 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-0.11美元,归母净利润-358.8万美元,同比去年增长87.68%
|
| 2024-03-05 |
详情>>
业绩披露：
2021年年报每股收益-1.66美元,归母净利润-2866.7万美元,同比去年增长-70.89%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.13美元,归母净利润-402.7万美元,同比去年增长81.81%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.54美元,归母净利润-1479万美元,同比去年增长5.81%
|
| 2023-08-07 |
股东大会：
将于2023-09-06召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split (the “Reverse Split”) of our common stock at a ratio in the range of one-for-five to one-for-twenty of our common stock with the exact ratio to be determined in the discretion of our board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion (the “Reverse Split Proposal”);
2.To approve, in accordance with applicable rules of the Nasdaq Stock Market, the potential future sale and issuance of shares of our common stock to Lincoln Park Capital Fund, LLC and its affiliates (“Lincoln Park”) in accordance with the pricing terms set forth in the common stock purchase agreement dated May 8, 2023 (the “Lincoln Park Purchase Agreement”) that would result in Lincoln Park owning in excess of 19.99% of the shares of our common stock outstanding immediately after giving effect to such sale (the “Nasdaq Stockholder Approval Proposal”);
3.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2023-05-10 |
详情>>
业绩披露：
2023年一季报每股收益-0.36美元,归母净利润-850.4万美元,同比去年增长10.23%
|
| 2023-03-08 |
股东大会：
将于2023-04-19召开股东大会
会议内容 ▼▲
- 1.To elect the three “Class II” directors named in the Company’s Proxy Statement to hold office until the Company’s 2026 Annual Meeting of Stockholders and until a successor is elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers;
4.To approve an amendment to the Company’s certificate of incorporation to increase its authorized shares of common stock from 40,000,000 to 60,000,000;
5.To approve, in accordance with applicable rules of the Nasdaq Stock Market, the issuance of shares of our common stock upon the potential future exercise of certain outstanding warrants held by Opaleye L.P. and its affiliates that would result in Opaleye L.P. and its affiliates owning in excess of 19.99% of the shares of our common stock outstanding immediately after giving effect to such exercise;
6.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
7.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2023-03-08 |
详情>>
业绩披露：
2020年年报每股收益-1.87美元,归母净利润-1677.5万美元,同比去年增长26.02%
|
| 2023-03-08 |
详情>>
业绩披露：
2022年年报每股收益-1.39美元,归母净利润-2913.5万美元,同比去年增长-1.63%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.08美元,归母净利润-2213.8万美元,同比去年增长-5.65%
|
| 2022-08-10 |
详情>>
业绩披露：
2022年中报每股收益-0.79美元,归母净利润-1570.3万美元,同比去年增长-12.14%
|
| 2022-05-11 |
详情>>
业绩披露：
2022年一季报每股收益-0.48美元,归母净利润-947.3万美元,同比去年增长-87.07%
|
| 2022-04-25 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the two “Class I” directors named in the Company’s Proxy Statement to hold office until the Company’s 2025 Annual Meeting of Stockholders and until a successor is elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers;
4.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.To elect the three “Class III” directors named in the Company’s Proxy Statement to hold office until the Company’s 2024 Annual Meeting of Stockholders and until a successor is elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers;
4.To approve an amendment to the TRACON Pharmaceuticals, Inc. 2015 Equity Incentive Plan;
5.To approve an amendment to the TRACON Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan;
6.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
7.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2020-10-30 |
股东大会：
将于2020-12-07召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s certificate of incorporation to increase its authorized shares of common stock from 20,000,000 to 40,000,000;
2.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2020-04-24 |
股东大会：
将于2020-06-10召开股东大会
会议内容 ▼▲
- 1.To elect two “Class II” directors named in the Company’s Proxy Statement to hold office until the Company’s 2023 Annual Meeting of Stockholders and until a successor is elected and qualified;
2.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve an amendment to the Company’s certificate of incorporation to increase its authorized shares of common stock from 20,000,000 to 70,000,000;
4.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2019-11-08 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2019-10-22 |
股东大会：
将于2019-11-06召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to (i) effect a reverse stock split of our common stock at a ratio in the range of one-for-five to one-for-twenty of our common stock, with the exact ratio to be determined in the discretion of our board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion, and (ii) reduce the number of authorized shares of our common stock in a corresponding proportion to the reverse stock split, rounded to the nearest whole share (collectively, the “Reverse Split Proposal”);
2.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2019-04-25 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.To elect a “Class I” Director named in the Company’s Proxy Statement to hold office until the Company’s 2022 Annual Meeting of Stockholders and until a successor is elected and qualified;
2.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2018-12-21 |
详情>>
内部人交易：
THEUER CHARLES股份增加49000.00股
|
| 2018-04-25 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.To elect three “Class III” Directors named in the Company’s Proxy Statement to hold office until the Company’s 2021 Annual Meeting of Stockholders and until their successors are elected and qualified;
2.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018; 3.To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2017-05-01 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1. To elect two “Class II” Directors named in the Company’s Proxy Statement to hold office until the Company’s 2020 Annual Meeting of Stockholders and until his successor is elected and qualified;
2. To ratify the selection of Ernst Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|
| 2016-04-21 |
股东大会：
将于2016-06-01召开股东大会
会议内容 ▼▲
- 1. To elect one “Class I” Director named herein to hold office until the Company’s 2019 Annual Meeting of Stockholders and until his successor is elected and qualified;
2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.
|